 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 04/09/2003 | | | | Statin Drug Treatment for Alzheimer's Supported by New Findings
topic: Statins and Alzheimer's Disease
April 9, 2003: New medical studies have bolstered the importance of Nymox Pharmaceutical Corporation's patent rights for statin use in Alzheimer's disease. Nymox holds U.S. patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. |
| 03/31/2003 | | | | Nymox Reports 2002 Financial Results
topic: Financial
March 31, 2003: Nymox Pharmaceutical Corporation announced today its financial results for the year ended December 31, 2002. Total product sales amounted to $356,162 in 2002, compared to $235,288 in 2001, an increase of over 50%. In addition there is $55,930 in deferred revenue, for which the Company has already received cash payment. Nymox reported a net loss for the year 2002 of $3,422,019, or $0.15 per share. |
| 03/27/2003 | | | | Dutton and Associates Initiates Coverage of Nymox With a "Buy" Recommendation
topic: Financial
March 27, 2003: Nymox Pharmaceutical Corporation announced today that J.M. Dutton & Associates LLC has initiated research coverage of the Company with a Buy rating. |
| 03/20/2003 | | | | Nymox's NicAlert™: A Valuable Tool for Smoking Cessation Programs
topic: Tobacco Exposure Tests
March 20, 2003: Nymox Pharmaceutical Corporation's NicAlert™ provides a valuable and needed tool for researchers and counselors working to develop more effective smoking cessation programs. |
| 03/19/2003 | | | | Nymox Announces New Successes with Diagnostic Platform
topic: R&D: Other Diagnostics
March 19, 2003: Nymox Pharmaceutical Corporation announced today that it has several new products in its diagnostic platform pipeline. Based on new successful development milestones, the Company will now be targeting these new product entities for commercial development. |
| 03/07/2003 | | | | New Second Hand Smoke Trial Results Confirm Usefulness and Accuracy of Nymox's NicAlert™
topic: Tobacco Exposure Tests
March 7, 2003: Nymox Pharmaceutical Corporation announced positive trial results for its NicAlert™ product. Clinical trials from multi-center trials have shown that the NicAlert™ is useful in detecting second-hand smoke exposure, as well as measuring the effects of smoking and tobacco product use in the urine. |
| 02/25/2003 | | | | Nymox Announces $5 Million Additional Financing
topic: Financial
February 25, 2003: Nymox Pharmaceutical Corporation announced today that the Company has secured commitment for an additional $5 million in private financing. |
| 02/20/2003 | | | | Excellent Results for Nymox's NicAlert™ Presented at National Meeting
topic: Tobacco Exposure Tests
February 20, 2003: A new study showing excellent results for Nymox's NicAlert™ device for measurement of tobacco product exposure is being presented at the Society for Research on Nicotine and Tobacco 9th Annual meeting in New Orleans. |
| 02/18/2003 | | | | Nymox Begins Phase I Human Studies for NX-1207 Prostate Treatment
topic: R&D: BPH (enlarged prostate) Treatments
February 18, 2003: Nymox Pharmaceutical Corporation announced today that it has begun Phase I safety studies for NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). |
| 01/28/2003 | | | | Nymox Develops New AlzheimAlert™ Test Kit for Overseas Markets
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
January 28, 2003: Nymox Pharmaceutical Corporation announced today that it has successfully developed a new kit for its AlzheimAlert™ test. The new kit is designed for export to foreign markets and will be commercially available by the end of March, 2003. |
|